Compare CRSR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | IOVA |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.3M | 968.6M |
| IPO Year | 2020 | N/A |
| Metric | CRSR | IOVA |
|---|---|---|
| Price | $6.84 | $2.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $9.94 | ★ $10.36 |
| AVG Volume (30 Days) | 1.1M | ★ 11.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,449,248,000.00 | $250,425,000.00 |
| Revenue This Year | $12.96 | $60.94 |
| Revenue Next Year | $9.28 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.79 | ★ 175.62 |
| 52 Week Low | $5.35 | $1.64 |
| 52 Week High | $13.02 | $9.30 |
| Indicator | CRSR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 49.35 |
| Support Level | $6.47 | $2.16 |
| Resistance Level | $6.84 | $2.34 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 94.03 | 38.46 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.